Investigational drug · Phase 2
ST-1898
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Renal Cell Carcinoma, Differentiated Thyroid Carcinoma, Unresectable or Metastatic Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "ST-1898"
First trial start
2023
Feb 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ST-1898", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Renal Cell Carcinoma
- Differentiated Thyroid Carcinoma
- Unresectable or Metastatic Melanoma
Approved drugs for the same conditions: Melanoma · Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "ST-1898" as an intervention, largest first.
- Study of ST-1898 in Advanced Renal Cell CarcinomaActive, not recruiting
Beijing Scitech-Mq Pharmaceuticals LimitedIndustry
NCT06127238 · 90 participants (planned) · Start Feb 7, 2023 · Primary completion Feb 2027
Drug: ST-1898 tablets · For: Advanced Renal Cell Carcinoma
Sites: Beijing, China
- A Study of ST-1898 for Unresectable or Metastatic MelanomaActive, not recruiting
Beijing Scitech-Mq Pharmaceuticals LimitedIndustry
NCT06359860 · 64 participants (planned) · Start Nov 7, 2023 · Primary completion Dec 2026
Drug: ST-1898 tablets · For: Unresectable or Metastatic Melanoma
Sites: Beijing, China
Beijing Scitech-Mq Pharmaceuticals LimitedIndustry
NCT06359847 · 60 participants (planned) · Start Nov 15, 2023 · Primary completion Dec 2027
Drug: ST-1898 tablets · For: Differentiated Thyroid Carcinoma
Sites: Beijing, China
- Study of ACC-1898 in Adult Participants With Advanced Solid TumorsNot yet recruiting
AccSalus Biosciences, Inc.Industry
NCT07252661 · 40 participants (planned) · Start Jan 2027 · Primary completion Jun 2028
Drug: ACC-1898 · For: Hepatocellular Carcinoma; Renal Cell Carcinoma; Thyroid Carcinoma, Medullary and 6 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Renal Cell Carcinoma
- CasdatifanAB521Phase 33 trials
Arcus Biosciences, Inc. · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma (RCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.